Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed
IntroductionSeveral new active substances (ASs) targeting neuroblastoma (NBL) are under study. We aim to describe the developmental and regulatory status of a sample of ASs targeting NBL to underline the existing regulatory gaps in product development and to discuss possible improvements.MethodsThe...
Main Authors: | Adriana Ceci, Rosa Conte, Antonella Didio, Annalisa Landi, Lucia Ruggieri, Viviana Giannuzzi, Fedele Bonifazi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1113460/full |
Similar Items
-
Treatment of High-Risk Neuroblastoma
by: Julie Krystal, et al.
Published: (2023-07-01) -
Association of Image-Defined Risk Factors with Clinical, Biological Features and Outcome in Neuroblastoma
by: Balanescu Laura, et al.
Published: (2022-11-01) -
Neuroblastoma in the Era of Precision Medicine: A Clinical Review
by: Andrew Wahba, et al.
Published: (2023-09-01) -
Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience
by: Emmad E. Habib, et al.
Published: (2012-02-01) -
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
by: Masayuki Imaya, et al.
Published: (2022-05-01)